| Home page | News | About us | Investment | Contact us | 
Position: China Medical City >> News >> Major CMC News >> The text
NAVIGATION
NEWS IN PICTURES

A Project of the Pro…

The Eighth China (Ta…

30 Projects Settled …

The 8th China (Taizh…
[Article with image]Key Product of Huaweite - "Hualankang" Officially Launched           ★★★
Key Product of Huaweite - "Hualankang" Officially Launched

Author:cmc Article source:cmc Click the number:245 Update time:2017-6-22 9:26:20

 On June 20, Huaweite (Jiangsu) Bio-pharmaceutical Co., Ltd. (Huaweite), an enterprise settled in CMC, held a new product conference to officially launch "Hualankang", a core vaccine product independently developed by the company.

"Hualankang" is the world's first veterinary drug produced with suspension culture process. The new drug has independent intellectual property rights and is used to prevent against highly pathogenic porcine reproductive and respiratory syndrome (commonly known as PRRS). The drug obtained a Category III new veterinary drug certificate from the Ministry of Agriculture in March 2016 and production approval from the Ministry of Agriculture in April 2017. The product has obtained an invention patent from China and other countries such as the United States and has been recognized as a new and high-tech product by the Science and Technology Department of Jiangsu Province.

Dr. Wu Hua, Huaweite's President and an expert of the Recruitment Program of Global Experts, summarized the features of "Hualankang" as five "truly": no immunosuppression-truly non-toxic, fast immune response - truly efficacious, no toxin dispersion - truly safe, suspension culture - truly effective, and heat-resisting protection - truly stable. "This key product is comparable with any PRRS vaccine in the market." Wu Hua said confidently. Due to protection of this star product, Huaweite didn't transfer the product technology to other companies, but decided to produce on its own. The sales of the product are expected to exceed 30 million yuan this year. After reaching full production capacity, the product will generate sales of no less than 50 million yuan every year.

NewsInputer:CMC    Editor:CMC 
  • Back ArticleNews:

  • Next ArticleNews:
  • 【Typeface:Small Big】【Comment】【Add favorite】【Mail this page】【Print】【Close
      The netizen comments:(Show only the latest 10. Review the content of view, has nothing to do with the stand!)

    | Set home | Add to Favorites | Contact the webmaster | About us |
    Copyright © 2014 Medmax.cn Inc. All rights reserved. Medmax.cn
    The competent units:Taizhou National Medical High-tech Development Zone
    Copyright: Taizhou pharmaceutical hi tech Industrial Park Management Committee
    Tel:0523-86200007;+86-15852977958;0523-86200142;+86-18262307755
    苏ICP备14026810号-1 苏B2-20070164
    回到最上头